Hwang SD, et al. - The appropriate dose of valganciclovir required to prevent cytomegalovirus (CMV) infection was investigated via performing a systematic review and meta-analysis. Researchers searched the Cochrane Central Register, MEDLINE, EMBASE, and PubMed databases up to April 15, 2017, and identified 450-mg dose of valganciclovir as effective in preventing post-transplantation CMV infection and decreasing drug-induced side effects such as leukopenia. Findings thus suggested this lower dose to have the potential to prevent cytomegalovirus infection and enhance the cost-effectiveness.